VONAPRUMENT
UNII 9HLL22LOX6

Substance Identification & Data

This profile provides standardized clinical and technical data for Vonaprument, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 9HLL22LOX6.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3050549-24-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

9HLL22LOX6

CAS Registry Number

3050549-24-8

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

VONAPRUMENT

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C224804

National Cancer Institute reference terminology for clinical and research data.

INN ID

13987

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

NO-54

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Vonaprument. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

VONAPRUMENT

Common Names & Synonyms

IMMUNOGLOBULIN FAB VH-G1(CH1-10H)_L-KAPPA, ANTI-(HOMO SAPIENS C1Q (COMPLEMENT C1Q) GLOBULAR HEAD REGION), MONOCLONAL ANTIBODY (VONAPRUMENT)

IMMUNOGLOBULIN FAB-G1KAPPA (VH-CH1_L-KAPPA), ANTI-(HOMO SAPIENS C1Q), HUMANIZED MONOCLONAL ANTIBODY FRAGMENT; FAB-G1 VH-CH1 CHAIN (1-229) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-64*01 (82.5%) -(IGHD) -IGHJ4*01 (92.9%) S123>T (116)/HOMO SAPIENS IGHV1-46*01 (79.4%) -(IGHD)-IGHJ6*01 (92.9%), CDR-IMGT (8.8.14) (26-33.51-58.97-110)) (1-121) -HOMO SAPIENS IGHG1*01 CH1-H (100%), G1M17 CH1 K120 (CH1 K120 (218) (122-219), HINGE 1-10 (220-229)) (122-229)), (224-214')-DISULFIDE WITH L-KAPPA LIGHT CHAIN (1'-214') (V-KAPPA (HOMO SAPIENS IGKV1-9*03 (80.9%) -IGKJ2*01 (100%), CDR-IMGT (6.3.9) (27-32.50-52.89-97)) (1'-107') -HOMO SAPIENS IGKC*01 (100%), KM3, A45.1 (153), V101 (191) (108'-214')), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO, NON-GLYCOSYLATED

IMMUNOGLOBULIN IGG1 FAB FRAGMENT, ANTI-(HUMAN COMPLEMENT C1Q) (HUMAN-MUS MUSCULUS MONOCLONAL ANX007 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL ANX007 .KAPPA.-CHAIN

VH-G1(CH1-10H) CHAIN ANTI-C1Q (H) (1-229) (VH MUSMUS/HOMSAP (MUS MUSCULUS IGHV1-64*01 (82.5%) -(IGHD) -IGHJ4*01 (92.9%) S123>T (116)/HOMO SAPIENS IGHV1-46*01 (79.4%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT (8.8.14) (26-33.51-58.97-110)) (1-121) -G1(CH1-10H) HOMO SAPIENS IGHG1*01 CH1 G1M17 K120 (CH1 K120 (218) (122-219), HINGE 1-10 (220-229)) (122-229)), (224-214')-DISULFIDE WITH L-KAPPA LIGHT CHAIN ANTI-C1Q (L') (1'-214') (V-KAPPA MUSMUS/HOMSAP (MUS MUSCULUS IGKV16-104*01 (89.5%) -IGKJ2*03 (90.9%) S120>Q (100')/HOMO SAPIENS IGKV1-9*03 (80.9%) -IGKJ2*01 (100%), CDR-IMGT (6.3.9) (27'-32'.50'-52'.89'-97')) (1'-107') -HOMO SAPIENS IGKC*01 (100%) KM3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')), PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, NON-GLYCOSYLATED

VONAPRUMENT [INN]

VONAPRUMENT [USAN]